Clearmind Medicine Submits Israeli Patent for Innovative Non-Hallucinogenic Neuroplastogen Therapy for Depression
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 16 2025
0mins
Source: Globenewswire
Patent Application Announcement: Clearmind Medicine Inc. has filed a patent application in Israel for a combination therapy using 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, targeting depression treatment in collaboration with Neurothera Labs Inc.
Focus on Mental Health: The therapy aims to address major depressive disorder, which affects over 280 million people globally, highlighting the need for innovative treatment options in mental health.
Intellectual Property Expansion: This filing adds to Clearmind's growing intellectual property portfolio, which includes 13 patents related to MEAI and N-Acylethanolamines for various conditions, including depression and addiction.
Company Overview: Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics for under-treated health issues, with a current portfolio of 31 granted patents and ongoing efforts to expand its intellectual property.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SPRC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SPRC
About SPRC
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SciSparc Subsidiary Receives Approval for CliniQuantum Acquisition
- Stock Surge: SciSparc Ltd. (SPRC) saw a 155% increase in stock price on Thursday, primarily driven by its subsidiary NeuroThera Labs receiving conditional approval from the TSX Venture Exchange for its acquisition, reflecting strong market optimism about the deal.
- Acquisition Details: NeuroThera plans to acquire approximately 54% of CliniQuantum in exchange for 56.6 million common shares, valued at about $9.46 million based on NeuroThera's 20-day volume-weighted average share price, indicating market recognition of its growth potential.
- Technological Innovation: CliniQuantum focuses on developing quantum simulation and Monte Carlo-based tools aimed at enhancing clinical trial precision by identifying patient subgroups most likely to respond to therapies, showcasing its cutting-edge position in clinical research.
- Exclusive Licensing Agreement: CliniQuantum's main asset is an exclusive worldwide license agreement with Quantum X Labs related to quantum simulation technologies for clinical trials, which will further strengthen its market competitiveness and drive future technological advancements.
See More
SciSparc Receives Approval to Acquire Stake in Israeli Tech Firm
- Acquisition Approval: SciSparc Ltd. (SPRC) received regulatory approval from the TSX Venture Exchange for its subsidiary NeuroThera Labs to acquire approximately 54% of CliniQuantum, valued at about $9.46 million, which is expected to enhance its competitive edge in clinical trial data analysis.
- Stock Surge: SPRC's shares soared nearly 140% to close at $10.55 on Thursday, reflecting strong market enthusiasm for its acquisition plans, which may attract further investor interest in its future growth prospects.
- Ebola Testing Progress: Co-Diagnostics Inc. (CODX) saw its stock rally over 50% for the third consecutive day amid the Ebola outbreak, indicating the effectiveness of its PCR assay strategy, which is likely to bolster the company's influence in public health.
- Clinical Trial Initiation: MiNK Therapeutics (INKT) dosed its first patient in a randomized phase 2 trial for acute lung injury, leading to an 18% stock increase, and this advancement could provide crucial data support for its future treatment options, strengthening its market position.
See More
SciSparc Acquires Controlling Interest in CliniQuantum
- Transaction Overview: SciSparc's majority-owned NeuroThera Labs has signed a share purchase agreement to acquire approximately 54.01% of CliniQuantum's shares for about $9.45 million, with the transaction expected to close within 30 days, marking a strategic expansion into quantum technology.
- Share Payment Structure: NeuroThera will issue 56,600,000 common shares to the Selling Shareholders, who may also receive up to $2.5 million in earn-out payments based on CliniQuantum's patent applications and fundraising achievements, further incentivizing innovation.
- Technological Innovation Potential: CliniQuantum focuses on leveraging quantum computing to enhance clinical trials, aiming to accelerate research by processing complex datasets, and this acquisition will strengthen SciSparc's competitive edge in the pharmaceutical industry and drive cutting-edge product development.
- Future Outlook: The transaction is anticipated to close by March 31, 2026, providing SciSparc an opportunity to enhance its market position in treating central nervous system disorders and achieve long-term growth through technological integration.
See More
Clearmind Unveils Patent for Innovative Weight Loss Therapy
- Patent for Innovative Therapy: Clearmind Medicine Inc. has announced an international patent application for a novel therapy combining MEAI and Palmitoylethanolamide, aimed at treating obesity and metabolic dysfunction-associated steatotic liver disease, potentially benefiting over 890 million obese adults worldwide.
- Significant Market Potential: The global weight loss drugs market was valued at approximately $37 billion in 2025 and is projected to reach $226 billion by 2035, indicating a strong demand for innovative alternatives, positioning Clearmind's new therapy to capture a share of this rapidly growing market.
- Strengthened Partnerships: The development of this therapy is bolstered by collaboration with NeuroThera Labs Inc., integrating Clearmind's MEAI platform with PEA to offer a safer and more cost-effective treatment option compared to GLP-1 agonists, enhancing the company's competitive edge in the biotech sector.
- Strategic Development Focus: CEO Dr. Adi Zuloff-Shani emphasized the company's commitment to developing innovative therapies to address underserved metabolic and neurological health issues, further solidifying its leadership position in the biotechnology industry.
See More
Sanofi Secures EU Approval for Teizeild, Demonstrating Significant Efficacy in Type 1 Diabetes
- New Drug Approval: Sanofi's Teizeild receives EU approval as the first disease-modifying therapy for Stage 2 Type 1 Diabetes, demonstrating a median delay of 48.4 months to Stage 3 T1D, significantly enhancing patient quality of life and strengthening the company's competitive position in diabetes treatment.
- FDA Approval: Fortress Biotech's ZYCUBO gains FDA approval as the first treatment for Menkes Disease, showing nearly an 80% reduction in mortality risk when used early, laying a solid foundation for future market expansion and revenue growth.
- Acquisition Deal: Boston Scientific's $14.5 billion acquisition of Penumbra reflects its strategic expansion in interventional therapies, expected to enhance its leadership in vascular treatments and drive future revenue growth.
- Clinical Trial Progress: Creative Medical's CELZ-201 shows significant improvement in 79% of patients in the ADAPT trial for chronic lower back pain, indicating the therapy's clinical potential and likely attracting further investment and partnership opportunities.
See More
SciSparc Ltd. Acquires Endoscopy Patents, Shares Drop 12.07%
- Patent Acquisition: SciSparc announced its definitive agreement to acquire a portfolio of patents and trademarks related to endoscopic systems and medical cameras, which is expected to enhance its presence in the medical device sector and facilitate expansion into new markets.
- Commercialization Strategy: The company plans to begin commercializing the acquired technologies immediately upon closing the deal, aiming to accelerate market penetration by replicating existing successful distribution models, particularly in North America, Europe, and Latin America.
- Equity Issuance Terms: Under the agreement, SciSparc will issue ordinary shares representing approximately 19.99% of its outstanding stock to the seller at closing, with the potential to issue pre-funded warrants to optimize its capital structure as needed.
- Expected Closing Timeline: SciSparc anticipates closing the acquisition by March 8, 2026, contingent upon satisfying customary conditions, including regulatory approvals, which will provide a significant opportunity for the company to enter new medical segments.
See More
SciSparc Subsidiary Receives Approval for CliniQuantum Acquisition
- Stock Surge: SciSparc Ltd. (SPRC) saw a 155% increase in stock price on Thursday, primarily driven by its subsidiary NeuroThera Labs receiving conditional approval from the TSX Venture Exchange for its acquisition, reflecting strong market optimism about the deal.
- Acquisition Details: NeuroThera plans to acquire approximately 54% of CliniQuantum in exchange for 56.6 million common shares, valued at about $9.46 million based on NeuroThera's 20-day volume-weighted average share price, indicating market recognition of its growth potential.
- Technological Innovation: CliniQuantum focuses on developing quantum simulation and Monte Carlo-based tools aimed at enhancing clinical trial precision by identifying patient subgroups most likely to respond to therapies, showcasing its cutting-edge position in clinical research.
- Exclusive Licensing Agreement: CliniQuantum's main asset is an exclusive worldwide license agreement with Quantum X Labs related to quantum simulation technologies for clinical trials, which will further strengthen its market competitiveness and drive future technological advancements.
See More
SciSparc Receives Approval to Acquire Stake in Israeli Tech Firm
- Acquisition Approval: SciSparc Ltd. (SPRC) received regulatory approval from the TSX Venture Exchange for its subsidiary NeuroThera Labs to acquire approximately 54% of CliniQuantum, valued at about $9.46 million, which is expected to enhance its competitive edge in clinical trial data analysis.
- Stock Surge: SPRC's shares soared nearly 140% to close at $10.55 on Thursday, reflecting strong market enthusiasm for its acquisition plans, which may attract further investor interest in its future growth prospects.
- Ebola Testing Progress: Co-Diagnostics Inc. (CODX) saw its stock rally over 50% for the third consecutive day amid the Ebola outbreak, indicating the effectiveness of its PCR assay strategy, which is likely to bolster the company's influence in public health.
- Clinical Trial Initiation: MiNK Therapeutics (INKT) dosed its first patient in a randomized phase 2 trial for acute lung injury, leading to an 18% stock increase, and this advancement could provide crucial data support for its future treatment options, strengthening its market position.
See More
SciSparc Acquires Controlling Interest in CliniQuantum
- Transaction Overview: SciSparc's majority-owned NeuroThera Labs has signed a share purchase agreement to acquire approximately 54.01% of CliniQuantum's shares for about $9.45 million, with the transaction expected to close within 30 days, marking a strategic expansion into quantum technology.
- Share Payment Structure: NeuroThera will issue 56,600,000 common shares to the Selling Shareholders, who may also receive up to $2.5 million in earn-out payments based on CliniQuantum's patent applications and fundraising achievements, further incentivizing innovation.
- Technological Innovation Potential: CliniQuantum focuses on leveraging quantum computing to enhance clinical trials, aiming to accelerate research by processing complex datasets, and this acquisition will strengthen SciSparc's competitive edge in the pharmaceutical industry and drive cutting-edge product development.
- Future Outlook: The transaction is anticipated to close by March 31, 2026, providing SciSparc an opportunity to enhance its market position in treating central nervous system disorders and achieve long-term growth through technological integration.
See More
Clearmind Unveils Patent for Innovative Weight Loss Therapy
- Patent for Innovative Therapy: Clearmind Medicine Inc. has announced an international patent application for a novel therapy combining MEAI and Palmitoylethanolamide, aimed at treating obesity and metabolic dysfunction-associated steatotic liver disease, potentially benefiting over 890 million obese adults worldwide.
- Significant Market Potential: The global weight loss drugs market was valued at approximately $37 billion in 2025 and is projected to reach $226 billion by 2035, indicating a strong demand for innovative alternatives, positioning Clearmind's new therapy to capture a share of this rapidly growing market.
- Strengthened Partnerships: The development of this therapy is bolstered by collaboration with NeuroThera Labs Inc., integrating Clearmind's MEAI platform with PEA to offer a safer and more cost-effective treatment option compared to GLP-1 agonists, enhancing the company's competitive edge in the biotech sector.
- Strategic Development Focus: CEO Dr. Adi Zuloff-Shani emphasized the company's commitment to developing innovative therapies to address underserved metabolic and neurological health issues, further solidifying its leadership position in the biotechnology industry.
See More
Sanofi Secures EU Approval for Teizeild, Demonstrating Significant Efficacy in Type 1 Diabetes
- New Drug Approval: Sanofi's Teizeild receives EU approval as the first disease-modifying therapy for Stage 2 Type 1 Diabetes, demonstrating a median delay of 48.4 months to Stage 3 T1D, significantly enhancing patient quality of life and strengthening the company's competitive position in diabetes treatment.
- FDA Approval: Fortress Biotech's ZYCUBO gains FDA approval as the first treatment for Menkes Disease, showing nearly an 80% reduction in mortality risk when used early, laying a solid foundation for future market expansion and revenue growth.
- Acquisition Deal: Boston Scientific's $14.5 billion acquisition of Penumbra reflects its strategic expansion in interventional therapies, expected to enhance its leadership in vascular treatments and drive future revenue growth.
- Clinical Trial Progress: Creative Medical's CELZ-201 shows significant improvement in 79% of patients in the ADAPT trial for chronic lower back pain, indicating the therapy's clinical potential and likely attracting further investment and partnership opportunities.
See More
SciSparc Ltd. Acquires Endoscopy Patents, Shares Drop 12.07%
- Patent Acquisition: SciSparc announced its definitive agreement to acquire a portfolio of patents and trademarks related to endoscopic systems and medical cameras, which is expected to enhance its presence in the medical device sector and facilitate expansion into new markets.
- Commercialization Strategy: The company plans to begin commercializing the acquired technologies immediately upon closing the deal, aiming to accelerate market penetration by replicating existing successful distribution models, particularly in North America, Europe, and Latin America.
- Equity Issuance Terms: Under the agreement, SciSparc will issue ordinary shares representing approximately 19.99% of its outstanding stock to the seller at closing, with the potential to issue pre-funded warrants to optimize its capital structure as needed.
- Expected Closing Timeline: SciSparc anticipates closing the acquisition by March 8, 2026, contingent upon satisfying customary conditions, including regulatory approvals, which will provide a significant opportunity for the company to enter new medical segments.
See More
